Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (Journal of Hematology & Oncology, (2020), 13, 1, (132), 10.1186/s13045-020-00964-5)

Musa Yilmaz; Mansour Alfayez; Courtney D. DiNardo; Gautam Borthakur; Tapan M. Kadia; Marina Y. Konopleva; Sanam Loghavi; Rashmi Kanagal-Shamanna; Keyur P. Patel; Elias J. Jabbour; Guillermo Garcia‑Manero; Naveen Pemmaraju; Sherry A. Pierce; Issa Ghayas; Nicholas J. Short; Guillermo Montalban-Bravo; Koichi Takahashi; Rita Assi; Ahmad S. Alotaibi; Maro Ohanian; Michael Andreeff; Jorge E. Cortes; Hagop M. Kantarjian; Farhad Ravandi; Naval G. Daver

ArticleOPEN ACCESS

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (Journal of Hematology & Oncology, (2020), 13, 1, (132), 10.1186/s13045-020-00964-5)

Journal of Hematology and Oncology

DOI: 10.1186/s13045-020-01023-9

2Citations

2Readers

Abstract

The original article [18] mistakenly contains duplicate references. The correct reference list can be viewed in this Correction article.

Cite

CITATION STYLE

APA

Yilmaz, M., Alfayez, M., DiNardo, C. D., Borthakur, G., Kadia, T. M., Konopleva, M. Y., … Daver, N. G. (2021, December 1). Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (Journal of Hematology & Oncology, (2020), 13, 1, (132), 10.1186/s13045-020-00964-5). Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-020-01023-9

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (Journal of Hematology & Oncology, (2020), 13, 1, (132), 10.1186/s13045-020-00964-5)

Abstract

Cite

Register to see more suggestions